We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

103 hedge funds and large institutions have $438M invested in CytomX Therapeutics in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

570% more call options, than puts

Call options by funds: $6.83M | Put options by funds: $1.02M

167% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 12

45% more capital invested

Capital invested by funds: $303M → $438M (+$136M)

24% more funds holding

Funds holding: 83 → 103 (+20)

16% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 25

82.02% less ownership

Funds ownership: 165.35% → 83.33% (-82%)

Holders
103
Holders Change
+20
Holders Change %
+24.1%
% of All Funds
1.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
29
Reduced
25
Closed
12
Calls
$6.83M
Puts
$1.02M
Net Calls
+$5.81M
Net Calls Change
+$4.08M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.9M
2
IC
Ikarian Capital
Texas
+$7.6M
3
PA
Perceptive Advisors
New York
+$6.05M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.86M
5
VA
VR Adviser
New York
+$3.58M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$13.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$9.04M
3
FFM
Fairmount Funds Management
Pennsylvania
-$8.85M
4
PM
Prosight Management
Texas
-$6.65M
5
VC
Vivo Capital
California
-$6.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
SS
101
SBI Securities
Japan
$271 +$2 +1 +1%
BNP Paribas Financial Markets
102
BNP Paribas Financial Markets
France
$54 – – –
TRCT
103
Tower Research Capital (TRC)
New York
$10 -$66.8K -29,658 -100%
Franklin Resources
104
Franklin Resources
California
– -$13.1M -5,769,230 Closed
FFM
105
Fairmount Funds Management
Pennsylvania
– -$8.85M -3,896,582 Closed
SCM
106
Soleus Capital Management
Connecticut
– -$2.96M -1,304,300 Closed
RAM
107
Readystate Asset Management
Illinois
– -$1.92M -844,643 Closed
EI
108
EAM Investors
California
– -$578K -254,580 Closed
BCM
109
Bridgeway Capital Management
Texas
– -$286K -126,000 Closed
Commonwealth Equity Services
110
Commonwealth Equity Services
Massachusetts
– -$121K -53,243 Closed
BCM
111
Bayesian Capital Management
New York
– -$114K -50,117 Closed
TSS
112
Two Sigma Securities
New York
– -$107K -47,311 Closed
Lazard Asset Management
113
Lazard Asset Management
New York
– -$98K -43,316 Closed
VF
114
Virtu Financial
New York
– -$80K -35,136 Closed
Federated Hermes
115
Federated Hermes
Pennsylvania
– -$903 -398 Closed
1 2 3 4
5

CTMX Hedge Fund Activity: Q3 2025 in Review

103 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2025, worth a combined $438M — up 45% from $303M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new CTMX positions and 12 closed out — a net gain of 20 holders — while 29 added to existing stakes and 25 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $13.9M. The largest seller was Franklin Resources, exiting entirely with an estimated $13.1M sold.

  • 103 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2025, up from 83 in Q2 2025.
  • Funds reported $438M of CytomX Therapeutics stock for Q3 2025, up 45% quarter-over-quarter.
  • 32 funds opened new CytomX Therapeutics positions in Q3 2025 and 12 closed out, a net change of +20 holders.
  • The largest CytomX Therapeutics buyer in Q3 2025 was Fidelity Investments, an estimated $13.9M added.
  • The largest CytomX Therapeutics seller in Q3 2025 was Franklin Resources, an estimated $13.1M sold.

Based on aggregated 13F filings for Q3 2025.